KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.
AZSTARYS was approved by the U.S. Food and Drug Administration (FDA) in March 2021...“The U.S. commercial launch of AZSTARYS is a significant milestone for KemPharm and an important advancement in the treatment of ADHD, a disease indication that has seen little innovation in recent years,” said Travis C. Mickle, Ph.D., President and CEO of KemPharm.
Other Articles in this Edition
Black women with ADHD start healing, with a diagnosis at last
The Pandemic Made It Harder to Spot Students With Disabilities. Now Schools Must Catch Up
What Employers Can Teach Schools About Neurodiversity
Pandemic Drives Drop in Prescription Drugs for Children
What to Know About ADHD and Dopamine
ADHD: The History of a Diagnosis
“It Transformed My Life”: Why A Rising Number Of Women Are Seeking ADHD Diagnoses